Acetylcholine in the cerebral cortex: Effects and clinical implications

Neurology

Volumn 75, Issue 7, 2010, Pages 659-665

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE; DONEPEZIL; DOPAMINE; GALANIN; GLUTAMIC ACID; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; NORADRENALIN; OREXIN; RIVASTIGMINE; XANOMELINE;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN NERVE CELL; CLINICAL TRIAL; DIFFUSE LEWY BODY DISEASE; HIPPOCAMPUS; HUMAN; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SENSORY CORTEX;

EID: 77955862403     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ee267e     Document Type: Article

References (44)

1. Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog Brain Res 2004;145:67-78.
2. Fadel JR. Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies. Behav Brain Res Epub 2010 Feb 16.
3. Hasselmo ME, Giocomo LM. Cholinergic modulation of cortical function. J Mol Neurosci 2006;30:133-135.
4. Jones BE. Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. Prog Brain Res 2004;145:157-169.
5. Sarter M, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci 2009;10:383-390.
6. Lawrence JJ. Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci 2008;31:317-327.
7. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cho-linergic neurons in the nucleus basalis. Ann Neurol 1981; 10:122-126.
8. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res Epub 2010 Jan 7.
9. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007;6:721-733.
10. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcho-line receptors as CNS drug targets. Pharmacol Ther 2008; 117:232-243.
11. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allo-steric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009;30:148-155.
12. Saper CB. Organization of cerebral cortical afferent systems in the rat. II. Magnocellular basal nucleus. J Comp Neurol 1984;222:313-342.
13. Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M. The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res Epub 2010 Feb 16.
14. Henny P, Jones BE. Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons. Eur J Neurosci 2008;27:654-670.
15. Zaborszky L, Gaykema RP, Swanson DJ, Cullinan WE. Cortical input to the basal forebrain. Neuroscience 1997; 79:1051-1078.
16. Zaborszky L, Buhl DL, Pobalashingham S, Bjaalie JG, Na-dasdy Z. Three-dimensional chemoarchitecture of the basal forebrain: spatially specific association of cholinergic and calcium binding protein-containing neurons. Neuro-science 2005;136:697-713.
17. Mesulam MM, Mash D, Hersh L, Bothwell M, Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol 1992;323:252-268.
18. Raghanti MA, Stimpson CD, Marcinkiewicz JL, Erwin JM, Hof PR, Sherwood CC. Cholinergic innervation of the frontal cortex: differences among humans, chimpanzees, and macaque monkeys. J Comp Neurol 2008;506: 409-424.
19. Lee MG, Hassani OK, Alonso A, Jones BE. Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep. J Neurosci 2005;25:4365-4369.
20. Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006;16:710-715.
21. Fisahn A, Yamada M, Duttaroy A, et al. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 2002;33:615-624.
22. Buzsaki G. Theta oscillations in the hippocampus. Neuron 2002;33:325-340.
23. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci 2007;8:45-56.
24. Melloni L, Molina C, Pena M, Torres D, Singer W, Rodriguez E. Synchronization of neural activity across cortical areas correlates with conscious perception. J Neurosci 2007;27:2858-2865.
25. Llinas RR, Steriade M. Bursting of thalamic neurons and states of vigilance. J Neurophysiol 2006;95:3297-3308.
26. Gulledge AT, Bucci DJ, Zhang SS, Matsui M, Yeh HH. M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons. J Neurosci 2009;29: 9888-9902.
27. Eggermann E, Feldmeyer D. Cholinergic filtering in the recurrent excitatory microcircuit of cortical layer 4. Proc Natl Acad Sci USA 2009;106:11753-11758.
28. Lucas-Meunier E, Monier C, Amar M, Baux G, Fregnac Y, Fossier P. Involvement of nicotinic and muscarinic receptors in the endogenous cholinergic modulation of the balance between excitation and inhibition in the young rat visual cortex. Cereb Cortex 2009;19:2411-2427.
29. Goard M, Dan Y. Basal forebrain activation enhances cortical coding of natural scenes. Nat Neurosci 2009;12: 1444-1449.
30. Kukolja J, Thiel CM, Fink GR. Cholinergic stimulation enhances neural activity associated with encoding but reduces neural activity associated with retrieval in humans. J Neurosci 2009;29:8119-8128.
31. Gais S, Born J. Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation. Proc Natl Acad Sci USA 2004;101:2140-2144.
32. De Bartolo P, Gelfo F, Mandolesi L, Foti F, Cutuli D, Petrosini L. Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. J Alzheimers Dis 2009;17:177-191.
33. Saper CB, German DC, White CL III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology 1985;35:1089-1095.
34. Watanabe T, Yamagata N, Takasaki K, et al. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res 2009;1249:222-228.
35. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity: a role for Wnt signaling pathway Neurobiol Dis 2004;17:337-348.
36. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci;11:77-86.
37. Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem 2009;108:1116-1125.
38. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273-278.
39. Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010;74:1416-1423.
40. Bosboom JL, Stoffers D, Stam CJ, Berendse HW, Wolters E. Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia. Clin Neurophysiol 2009;120:910-915.
41. Voisin T, Reynish E, Portet F, Feldman H, Vellas B. What are the treatment options for patients with severe Alzheimer's disease? CNS Drugs 2004;18:575-583.
42. Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors.] Nervenarzt 2008;79:36-39, 42-136
43. Bodick NC, Offen WW, Levey AI, et al. Effects of xa-nomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
44. Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rode-fer JS. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs 2008;9:47-56.